Clearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement Disorder
Key Highlights
- ➤Japan patent application covers 3-MMC-based treatment for dyskinesia
- ➤Application includes 3-MMC combinations with Palmitoylethanolamide (PEA)
- ➤Clearmind and NeuroThera collaborate on PEA-integrated therapeutic programs
- ➤Clearmind’s portfolio includes nineteen patent families and 32 granted patents
Expert Statements
Adi Zuloff-Shani, Chief Executive Officer of Clearmind
“Our strategy is to build robust intellectual property protection around our novel therapeutic platforms and their broad potential across neurological disorders”
Adi Zuloff-Shani, Chief Executive Officer of Clearmind
“The publication of the patent application in Japan and strengthens our global IP position for our 3-MMC-based approach to dyskinesia, including its combination with PEA.”
Published patent application covers 3-MMC-based treatment of dyskinesia, including in combination with Palmitoylethanolamide (PEA)
Vancouver, Canada, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (the “Company”), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogen for scalable treatment of neuropsychiatric, metabolic, and addiction disorders including Alcohol Use Disorder (“AUD”), today announced the publication of a patent application in Japan covering novel compositions and methods for treating dyskinesia, a neurological movement disorder characterized by involuntary movements. The published patent application covers the use of 3-Methylmethcathinone (“3-MMC”) for preventing, treating, or reducing dyskinesia symptoms, including pharmaceutical compositions comprising 3-MMC. The application also includes claims for combinations of 3-MMC with N-acylethanolamines, notably Palmitoylethanolamide (“PEA”, a compound with established anti‑inflammatory and neuroprotective properties.
Get started
Create a free account to read the full story.